Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinomaLijuan Liu(Wuhan University), Fan Zhu(Wuhan University)OncotargetMarch 30, 201710.18632/oncotarget.16702Cited by 15SaveCiteExport RISWatch citationsRelated PapersVariant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation|Hepatology|2012|85Antagonizing STAT5B dimerization with an osmium complex|Scientific Reports|2016|16